Castle Biosciences CSTL Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Castle Biosciences’s reported figures.
Based on the most recent quarter.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's debt-to-equity?
- Castle Biosciences (CSTL) reported debt-to-equity of 0.1× in Q1 2026.
- How has Castle Biosciences's debt-to-equity changed year-over-year?
- Castle Biosciences's debt-to-equity increased by 35.6% year-over-year, from 0.1× to 0.1×.
- What is the long-term trend for Castle Biosciences's debt-to-equity?
- Over 4 years (2021 to 2025), Castle Biosciences's debt-to-equity has grown at a 40.4% compound annual growth rate (CAGR), from 0× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.